Serotonin transporter and 5-hydroxytryptamine receptors (1A, 2A, 2B, 7) (SERT/5-HT1A/5-HT2A/5-HT2B/5-HT7)

This target profile represents a multimodal pharmacological approach within the serotonergic system, combining the inhibition of the serotonin transporter (SERT) with the modulation of several 5-hydroxytryptamine (5-HT) receptor subtypes. SERT (SLC6A4) is responsible for the reuptake of serotonin from the synaptic cleft, and its inhibition is the primary mechanism of traditional SSRIs (Sanchez et al., 2015, Psychopharmacology). The addition of 5-HT1A agonism and antagonism at 5-HT2A, 5-HT2B, and 5-HT7 receptors serves to enhance the antidepressant effect, improve cognitive symptoms, and potentially mitigate side effects like sexual dysfunction or sleep disturbances (Stahl, 2013, Stahl's Essential Psychopharmacology). Drugs targeting this specific constellation, such as the multimodal antidepressant vortioxetine or certain atypical antipsychotics like ziprasidone, leverage these interactions to influence not only serotonin but also downstream release of glutamate, GABA, dopamine, and acetylcholine in the prefrontal cortex (Bang-Andersen et al., 2011, Journal of Medicinal Chemistry). This broad modulation is particularly relevant for treating treatment-resistant depression and the cognitive deficits associated with psychiatric disorders. While highly effective, the complexity of this profile requires careful monitoring for serotonin syndrome and metabolic or cardiovascular side effects depending on the specific drug's affinity for each component (Lieberman, 2004, Journal of Clinical Psychiatry).

Other names

Serotonergic system multimodal profileSLC6A4 and HTR1A/HTR2A/HTR2B/HTR7 complexMultimodal serotonergic targetSerotonin modulator and stimulator (SMS) profile

Inhibition of serotonin reuptake via SERT combined with agonism or antagonism of specific 5-HT receptor subtypes to modulate synaptic neurotransmitter levels and downstream signaling.